CAMBRIDGE, Mass.--(BUSINESS WIRE)--Altus Pharmaceuticals Inc. (NASDAQ: ALTU), a biopharmaceutical company focused on oral and injectable protein therapeutics for patients with gastrointestinal and metabolic disorders, announced today that it has signed a long-term agreement with Lonza Group Ltd (SWX: LONN), to commercially manufacture Altus’ ALTU-135 drug substances at Lonza’s facility in Kourím, Czech Republic. ALTU-135, the Company’s orally administered enzyme replacement therapy in development for patients with pancreatic insufficiency, is the drug product that results after blending three drug substance enzymes: protease, lipase and amylase. This consistent and pure enzyme combination is designed to improve fat, protein and carbohydrate absorption in pancreatic insufficient individuals. ALTU-135 is intended to replace missing digestive enzymes to promote and maintain proper digestion and growth in affected patients.
